Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$3.52M$3.52M— vs Q3 2021 Net Income-$81.75M-$81.75MN/M vs Q3 2021 EPS Diluted-$1.49-$1.49N/M vs Q3 2021 Operating Income-$91,090,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$71,389,000N/M Margins · derivedOperating margin-2590.7%
Net margin-2325.0%
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end